New Products December 2021

New Wound Imaging Device Provides Updated Features And Services

Moleculight, Inc. recently launched MolecuLightDX™, a complement to MolecuLight i:X® wound imaging device. According to the company CEO in a recent press release, “The i:X and DX are the only commercially-available point-of-care devices to enable real-time detection of elevated bacterial burden in wounds.”

The company shares that the DX device provides integration with multiple EMRs, an easy-to-use interface and workflow that allows for configuration and tracking, and a docking system for easier charging. It also has the ability to measure wound area without the need for wound stickers. The press release goes on to say that the clients will continue to receive the same support as for the i:X device, including patient training, online courses and remote support.

Moleculight also relates that the DX device also has an applicable reimbursement pathway (as does the i:X) in the United States. The press release shares that this pathway includes two physician CPT^® codes for “fluorescence wound imaging for bacterial presence, location, and load,” and facility payment for hospital outpatient departments and ambulatory surgical center settings. The MolecuLightDX has FDA clearance for sale in the United States, as well as the CE Mark and Health Canada approval for commercial availability in Europe and Canada. 

Company: Moleculight

Product: Moleculight DX™

For more info, visit www.moleculight.com

PAD Screening System Focuses On Population Health Management

PADnet™ Xpress is a portable, fast and flexible way to screen for PAD, according to Biomedix^®. They share that testing is possible in under two minutes. According to the company website, the tests automatically sync to their population health platform, where users can add data and print their studies from a central, cloud- and web-based interface. Biomedix says that PADnet Xpress does not have a complicated login, uses only one editable field, a single-screen user interface and has live signal quality feedback. Also, they note that segments of the system auto-complete, which guides users through the test.

Biomedix points out that the testing sensor is sensitive, even for cold toes, and features an ambient light-filtering technology. Users can attach as much or as little demographic info as they wish to each test. They go on to say that over 20 years of PAD diagnostics went into the software, allowing the system to encourage users to work smarter. The system also supports assessments for depression, fall risk, personality disorder and social determinants of health.

Biomedix adds that their secure system is HITRUST-certified. Although not yet indicated for home use, the company website relates that PADnet Xpress successfully passed the 60601-1-11 test for compliance with electrical safety standards for home use. 

Company: Biomedix^®

Product: PADnet Xpress

For more info, visit www.biomedix.com

Fish Skin Graft Now Available For Soft Tissue Surgical Reinforcement And Repair

Could a new application of a known modality provide an option for soft tissue augmentation and repair? Kerecis^® recently received FDA authorization to market Kerecis Omega3 SurgiBind™ in the US. This implantable fish-skin graft has indications for implantation to reinforce and repair soft tissue in plastic and reconstructive surgeries.

Kerecis Omega3 SurgiBind is the company’s first implantable medical device aimed at the surgical market. According to the company, Kerecis Omega3 SurgiBind aids surgeons in managing the risk of complications and improving outcomes.

“The fish-skin technology provides rapid incorporation and cell ingrowth, accelerated neovascularization and faster wound closure, all of which speed full tissue remodeling,” says Kerecis.

Kerecis founder and CEO Fertram Sigurjonsson adds, “This new product re-enforces our entry into the surgical market and demonstrates that the benefits of our technology extend beyond treating severe wounds and preventing amputations.”

The company shares that Kerecis Omega3 is intact fish skin that can convert into living tissue when grafted onto damaged human tissue. They add that no disease transfer risk exists between cold-water fish and humans, so there is only gentle processing of Kerecis fish skin, allowing retention of its similarity to human tissue and preservation of the original 3D structure. In turn, they add that this also results in maintenance of natural strength, complexity and molecules such as Omega3 and other fatty acids..

Kerecis Omega3 SurgiBind is the company’s first implantable medical device aimed at the surgical market. In addition to SurgiBind, Kerecis has three other products for surgical applications: Kerecis Omega3 SurgiClose™, SurgiClose Micro™ and GraftGuide™.

The introduction of SurgiBind further strengthens the entry of Kerecis into the surgical market and demonstrates the wider applicability of the Kerecis Omega3 technology beyond skin grafts for severe wound care. 

Company: Kerecis^®

Product: Kerecis^®Omega3 SurgiBind™

For more info, visit www.kerecis.com